Ethnic minority inequalities in access to treatments for schizophrenia and schizoaffective disorders. Findings from a nationally representative cross-sectional study
File(s)s12916-018-1035-5.pdf (418.69 KB)
Published version
Author(s)
Das-Munshi, Jayati
Bhugra, Dinesh
Crawford, Mike
Type
Journal Article
Abstract
Background
Ethnic minority service users with schizophrenia and schizoaffective disorders may experience inequalities in care. There have been no recent studies assessing access to evidence-based treatments for psychosis amongst the main ethnic minority groups in the UK.
Methods
Data from nationally representative surveys from England and Wales, of 10512 people with a clinical diagnosis of schizophrenia or schizoaffective disorders, were used for analyses. Multi-level multivariable logistic regression analyses were used to assess ethnic minority inequalities in access to pharmacological treatments, psychological interventions, shared decision making and care planning, taking into account a range of potential confounders.
Results
Compared with White service users, Black service users were more likely prescribed depot/ injectable antipsychotics (odds ratio:1.56 (95% confidence interval:1.33-1.84). Black service users with treatment-resistance were less likely to be prescribed clozapine (odds ratio: 0.56 (95% confidence interval: 0.39-0.79)). All ethnic minority service users, except those of mixed ethnicity, were less likely to be offered cognitive behavioural therapy, compared to White service users. Black service users were less likely to have been offered family therapy and Asian service users were less likely to have received copies of care plans (odds ratio:0.50 (95% confidence interval:0.33-0.76)), compared to White service users. There were no clinician-reported differences in shared decision making, across each of the ethnic minority groups.
Conclusions
Relative to White service users, ethnic minority service users with psychosis were generally less likely to be offered a range of evidence-based treatments for psychosis, which included pharmacological and psychological interventions as well as involvement in care-planning.
Ethnic minority service users with schizophrenia and schizoaffective disorders may experience inequalities in care. There have been no recent studies assessing access to evidence-based treatments for psychosis amongst the main ethnic minority groups in the UK.
Methods
Data from nationally representative surveys from England and Wales, of 10512 people with a clinical diagnosis of schizophrenia or schizoaffective disorders, were used for analyses. Multi-level multivariable logistic regression analyses were used to assess ethnic minority inequalities in access to pharmacological treatments, psychological interventions, shared decision making and care planning, taking into account a range of potential confounders.
Results
Compared with White service users, Black service users were more likely prescribed depot/ injectable antipsychotics (odds ratio:1.56 (95% confidence interval:1.33-1.84). Black service users with treatment-resistance were less likely to be prescribed clozapine (odds ratio: 0.56 (95% confidence interval: 0.39-0.79)). All ethnic minority service users, except those of mixed ethnicity, were less likely to be offered cognitive behavioural therapy, compared to White service users. Black service users were less likely to have been offered family therapy and Asian service users were less likely to have received copies of care plans (odds ratio:0.50 (95% confidence interval:0.33-0.76)), compared to White service users. There were no clinician-reported differences in shared decision making, across each of the ethnic minority groups.
Conclusions
Relative to White service users, ethnic minority service users with psychosis were generally less likely to be offered a range of evidence-based treatments for psychosis, which included pharmacological and psychological interventions as well as involvement in care-planning.
Date Issued
2018-04-18
Date Acceptance
2018-03-13
Citation
BMC Medicine, 2018, 16
ISSN
1741-7015
Publisher
BioMed Central
Journal / Book Title
BMC Medicine
Volume
16
Copyright Statement
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
License URL
Subjects
Science & Technology
Life Sciences & Biomedicine
Medicine, General & Internal
General & Internal Medicine
Inequalities
Race
Ethnic minority
Schizophrenia
Schizoaffective disorders
Treatments
Prescribing
CBT
Family therapy
Care plans
RANDOMIZED CONTROLLED-TRIAL
HEALTH-SERVICES
MENTAL-ILLNESS
PSYCHOSIS
CARE
METAANALYSIS
THERAPY
PEOPLE
LONDON
PATHWAYS
11 Medical And Health Sciences
Publication Status
Published
Article Number
ARTN 55
Date Publish Online
2018-04-18